EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants

Chad A Bousman iD, James M Stevenson iD, Laura B Ramsey iD, Katrin Sangkuhl iD, J Kevin Hicks iD, Jeffrey R Strawn iD, Ajeet B Singh, Gualberto Ruaño iD, Daniel J Mueller iD, Evangelia Eirini Tsermpini iD, Jacob T Brown iD, Gillian C Bell und 6 weitere

Clinical Pharmacology & Therapeutics · 2023-07 · 114 (1) · 51-68

DOI: 10.1002/cpt.2903 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 30.05.2023. Verfasst von Chad A Bousman und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Major Depressive Disorder. Die Arbeit wurde bisher 497-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS, NIGMS NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake inhibitors (SSRIs; i.e., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), serotonin and norepinephrine reuptake inhibitors (i.e., desvenlafaxine, duloxetine, levomilnacipran, milnacipran, and venlafaxine), and serotonin modulators with SSRI‐like properties (i.e., vilazodone and vortioxetine) are primary pharmacologic treatments for major depressive and anxiety disorders. Genetic variation in CYP2D6 , CYP2C19 , and CYP2B6 influences the metabolism of many of these antidepressants, which may potentially affect dosing, efficacy, and tolerability. In addition, the pharmacodynamic genes SLC6A4 (serotonin transporter) and HTR2A (serotonin‐2A receptor) have been examined in relation to efficacy and side effect profiles of these drugs. This guideline updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing and summarizes the impact of CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A genotypes on antidepressant dosing, efficacy, and tolerability. We provide recommendations for using CYP2D6 , CYP2C19 , and CYP2B6 genotype results to help inform prescribing these antidepressants and describe the existing data for SLC6A4 and HTR2A , which do not support their clinical use in antidepressant prescribing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Selective Serotonin Reuptake InhibitorsMajor Depressive DisorderHumansCytochrome P-450 CYP2D6Cytochrome P-450 CYP2B6PharmacogeneticsCytochrome P-450 CYP2C19Serotonin Plasma Membrane Transport ProteinsSerotoninAntidepressive AgentsCitalopramGenotype

Substanzen

Selective Serotonin Reuptake InhibitorsCytochrome P-450 CYP2D6Cytochrome P-450 CYP2B6Cytochrome P-450 CYP2C19Serotonin Plasma Membrane Transport ProteinsSerotoninAntidepressive AgentsCitalopramCYP2B6 protein, humanCYP2C19 protein, human

Autor:innen und Institutionen

  • Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.
  • Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
  • Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.
  • Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
  • Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.
  • Mathison Centre for Mental Health Research and Education, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Chad A Bousman, James M Stevenson, Laura B Ramsey, Katrin Sangkuhl, J Kevin Hicks, Jeffrey R Strawn, Gualberto Ruaño, Daniel J Mueller, Evangelia Eirini Tsermpini, Jacob T Brown, J Steven Leeder, Andrea Gaedigk, Stuart A Scott, Teri E Klein, Kelly E Caudle, Jeffrey R Bishop

Förderung

  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • NICHD NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health
  • National Institute of Child Health and Human Development
  • Patient-Centered Outcomes Research Institute

Zitieren

APA

Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., Brown, J. T., Bell, G. C., Leeder, J. S., Gaedigk, A., Scott, S. A., Klein, T. E., Caudle, K. E., & Bishop, J. R. (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clinical Pharmacology & Therapeutics, 114(1), 51-68. https://doi.org/10.1002/cpt.2903

Vancouver

Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clinical Pharmacology & Therapeutics. 2023;114(1):51-68. doi:10.1002/cpt.2903

BibTeX
@article{Bousman2023,
  author = {Bousman, Chad A and Stevenson, James M and Ramsey, Laura B and Sangkuhl, Katrin and Hicks, J Kevin and Strawn, Jeffrey R and Singh, Ajeet B and Ruaño, Gualberto and Mueller, Daniel J and Tsermpini, Evangelia Eirini and Brown, Jacob T and Bell, Gillian C and Leeder, J Steven and Gaedigk, Andrea and Scott, Stuart A and Klein, Teri E and Caudle, Kelly E and Bishop, Jeffrey R},
  title = {Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {114},
  number = {1},
  pages = {51--68},
  doi = {10.1002/cpt.2903}
}
Kostenlos starten →